ArticleLangenbeck's archives of surgery2026
Efficacy and clinical outcomes of proximal splenic artery embolization in patients with chemotherapy induced thrombocytopenia.
Article in Langenbeck's archives of surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis retrospective study aims to investigate efficacy and clinical outcomes of proximal splenic artery embolization (PSAE) in patients with chemotherapy induced thrombocytopenia (CIT).
methodsPSAE was performed in thirteen patients with CIT (6:7, M:F; median age: 55y; range: 39-76y) with underlying malignancy (colorectal carcinoma: n = 6; pancreatic carcinoma: n = 3; other: n = 4). Median platelet counts were calculated prior to chemotherapy, at nadir resulting in chemotherapy discontinuation, prior to SAE, immediately and at the maximum following SAE. Additionally, the time until re-initiation of chemotherapy was calculated.
resultsTechnical success was 100%, with no adverse events or 30-day mortality. Vascular plugs (n = 9) and coils (n = 11) were the most frequently used devices. Median platelet count pre-chemotherapy was 201 × 10(9)/L (range: 100-423 × 10(9)/L), platelet count nadir was 45 × 10(9)/L (range: 21-69 × 10(9)/L), and pre-SAE platelet count was 82 × 10(9)/L (range: 45-171 × 10(9)/L). After proximal SAE, median platelet count increased significantly (110 × 10(9)/L; range: 68-169 × 10(9)/L) compared to pre-procedure platelet count (p = 0.027). Median platelet count at the maximum at follow-up was 191 × 10(9)/L (range: 31-518 × 10(9)/L). Chemotherapy was re-initiated after a median of 15 days (range: 7-50d).
conclusionProximal SAE is a safe and effective treatment option in patients with CIT, with potential benefits in early re-initiation of chemotherapy. Further studies should be conducted to evaluate the longer-term effects of the procedure, further identify eligible patients, and compare to distal SAE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.